late cornified envelope 2DGenealiases: LEP12 · SPRL1A
Q-omics provides the consensus-scored LCE2D profile across patient tissues and cancer cell-line models. LCE2D expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LCE2D is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, LCE2D RNA expression shows 9,914 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BLCA, KIRP, and COAD as cancer lineages where LCE2D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCE2D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCE2D survival associations across molecular data types. LCE2D RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCE2D RNA expression–survival associations across cancer types. High LCE2D expression shows unfavorable associations in BLCA, SKCM, STAD, OV and LUSC, but favorable associations in ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LCE2D RNA expression.
This table summarizes LCE2D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LCE2D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCE2D shows lower tumor expression in KIRP, KIRC, CHOL and KICH and higher tumor expression in LUSC. The KIRP box plot shows higher LCE2D RNA expression in normal versus tumor tissue (log2 FC = −0.378, t-test p < 0.001).
This table shows molecular features associated with LCE2D in patient tissues and cancer cell lines. In patient samples, LCE2D shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LCE2D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
